Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Support grows for bill letting pharmacists initiate and manage buprenorphine in community pharmacies
Summary
Researchers, pharmacists and public‑health experts told the committee that S.1635 would expand access to buprenorphine for opioid use disorder by allowing pharmacists, under collaborative agreements, to initiate and continue treatment in community settings.
Supporters of S.1635 told the Joint Committee on Public Health that authorizing pharmacists to start and maintain patients on buprenorphine—under collaborative practice agreements and with appropriate payment—would expand access to life‑saving treatment.
Jeffrey Paul Bratberg, a pharmacist and university faculty member, described pharmacists’ successful public-health roles during COVID‑19 and their existing collaborative practice work in hospital settings. “Let pharmacists…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
